alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                  EXHIBIT 10.8

               AGREEMENT BETWEEN THE COMPANY AND TIMOTHY P. HICKS

We are pleased to offer you the position of Executive Vice President, Marketing,
for Data Dimensions, Inc. You will be located in Bellevue and will report
directly to me. It is hoped that you will commence your employment on Monday,
October 12, 1997, or earlier, if practicable.

Your compensation package will consist of:

o    Monthly salary of $13,750 (annual $165,000), paid in accordance with our
     payroll schedule, which is currently bi-weekly as earned.

o    You will be eligible for a performance bonus of between 30% and 50% of your
     base annualized salary for fiscal year 1999, commencing January 1, 1999.
     This bonus will be predicated upon meeting mutually agreed-upon performance
     objectives.

o    Options to purchase 80,000 shares of Data Dimensions, Inc., common stock
     subject to the approval of the Board of Directors. The exercise price of
     the options will be based on the market close on the day you begin
     employment with Data Dimensions, Inc. The options will vest in quarters
     (25%), annually, on the anniversary date of your employment.

     In the event your employment is terminated for other than cause, your
     salary, benefits and stock options will be extended for six months. In the
     event there is a change in Company ownership, your salary and benefits will
     be extended for six months and your stock options will be completely
     vested.

     Company standard vacation, group medical and other benefits, as outlined in
     the Employee Handbook (enclosed).

A moving and living allowance of $15,000 will be provided to you to allocate in
any way you see fit. (It is our understanding that actual expenses incurred in
the relocation are tax deductible. The remainder, if any, will be considered
current income.)

There are other details to be discussed. I suggest you plan to meet with me
before your official start date. Please schedule a convenient time with my
assistant Carol Stockton.

Please indicate your acceptance by signing below and returning a copy to me.

Tim, we look forward to working with you as we continue to make Data Dimensions
a success.

Sincerely,

DATA DIMENSIONS, INC.

/S/  LARRY W. MARTIN
--------------------
Larry W. Martin,
Chief Executive Officer and President

Accepted and Agreed to by:


/S/  TIMOTHY P. HICKS                               September 28, 1998
---------------------                               ------------------
Timothy P. Hicks                                    Date
I 

118TH CONGRESS 

2D SESSION H. R. 7576 

To amend section 6323 of title 5, United States Code, to increase the 

rate at which military leave accrues for members of the Reserve and 

the National Guard from 15 days to 30 days per year, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 7, 2024 

Mr. VAN ORDEN (for himself and Mr. PAPPAS) introduced the following bill; 

which was referred to the Committee on Oversight and Accountability 

A BILL 

To amend section 6323 of title 5, United States Code, to 

increase the rate at which military leave accrues for 

members of the Reserve and the National Guard from 

15 days to 30 days per year, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Reserve and National 

5 Guard Military Leave Enhancement Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7576 IH

1 SEC. 2. INCREASE IN LEAVE ACCRUAL FOR MILITARY SERV2 ICE OF CERTAIN FEDERAL EMPLOYEES. 

3 Section 6323(a)(1) of title 5, United States Code, is 

4 amended— 

5 (1) by striking ‘‘15 days per fiscal year’’ and 

6 inserting ‘‘30 days per fiscal year’’; and 

7 (2) by striking ‘‘until it totals 15 days at the 

8 beginning of a fiscal year’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 573.660 Methyl glucoside-coconut oil ester. Methyl glucoside-coconut oil ester may be safely used in accordance with the following conditions: ( a ) The additive meets the specifications prescribed in § 172.816 of this chapter.
( b ) It is used as a surfactant in molasses intended for use in animal feed at a level not to exceed 320 parts per million.
<PAGE>

                                                                  EXHIBIT 32 (a)

CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection  with the Quarterly  Report of Northland  Cable  Properties  Seven
Limited  Partnership  (the  "Partnership")  on Form  10Q for  the  period  ended
September 30, 2005 as filed with the Securities  and Exchange  Commission on the
date hereof (the "Form 10-Q"),  I, John  Whetzell,  Chief  Executive  Officer of
Northland Communications Corporation,  the General Partner, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that;

     (1)  The Form 10-Q fully complies with the  requirements  of Section 13 (a)
          or (15(d) of the  Securities  Exchange  Act of 1934 (15 U.S.C.  78m or
          78(d)); and

     (2)  The  information  contained  in the Form 10-Q  fairly  presents in all
          material respects,  the financial  condition and results of operations
          of the Partnership.

DATE: 11-14-05

/s/ JOHN S. WHETZELL
    ----------------
    John S. Whetzell
    Chief Executive Officer

A signed  original of this  written  statement  required by Section 906 has been
provided to Northland  Cable  Properties  Seven Limited  Partnership and will be
retained by Northland Cable Properties  Seven Limited  Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
EXHIBIT 3.8


            ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF
                   CENTRAL WIRELESS, INC., A UTAH CORPORATION


      Pursuant to the  provisions  of Section  16-10a-1006  of the Utah  Revised
Business  Corporation  Act, the  undersigned  corporation  (the  "Corporation"),
hereby adopts the following amendment to its Articles of Incorporation:

      The first paragraph of Article IV shall be amended to read as follows:

                         ARTICLE IV - AUTHORIZED SHARES

      The  total  number of shares of stock  which the  Corporation  shall  have
authority to issue is Two Billion Ten Million (2,010,000,000) shares, consisting
of Two  Billion  (2,000,000,000)  shares of Common  Stock  having a par value of
$0.001 per share, and Ten Million  (10,000,000) shares of Preferred Stock having
a par value of $0.01 per share.

      The foregoing  amendment was adopted on September 25, 2003.  The number of
issued  and  outstanding  shares  entitled  to vote on these  Amendments  to the
Articles of Incorporation was 237,930,144 of which  119,097,462  shares voted in
favor and none opposed.

      IN  WITNESS   WHEREOF,   the  foregoing   Amendment  to  the  Articles  of
Incorporation has been executed this 25th day of September, 2003.


                                        CENTRAL WIRELESS, INC.


                                        BY: /S/ Kenneth W. Brand
                                           -------------------------------------
                                           NAME:  Kenneth W. Brand
                                           TITLE: Chief Executive Officer


                                       1
<PAGE>   1
                                                            EXHIBIT 11

COMPUTATION OF PER SHARE EARNINGS

The computation of primary earnings per share, (restated where appropriate to
give effect to the 10% stock dividend distributed February 28, 1997) is as
follows (in thousands):
<TABLE>
<CAPTION>

                                        Three Months Ended      Nine Months Ended
                                             June 30,                June 30
                                        ------------------      ------------------
                                         1997        1996        1997        1996
                                        ------      ------      ------      ------
<S>                                     <C>         <C>         <C>         <C>   
Weighted average shares
outstanding                              5,286       5,631       5,265       5,677


Add equivalent shares for
stock options (a)                        1,086         962       1,064         971
                                        ------      ------      ------      ------

Average shares outstanding
for computation of primary
earnings per share                       6,372       6,593       6,329       6,648
                                        ======      ======      ======      ======

Income from continuing                  $6,404      $4,188      $9,926      $7,798
operations                              ======      =======     ======      ======


Net Income                              $6,404      $4,363      $9,926      $7,950
                                        ======      =======     ======      ======



PRIMARY EARNINGS PER COMMON SHARE:

From continuing operations              $ 1.01      $  .64      $ 1.57      $ 1.17
                                        ======      ======      ======      ======

Net Income                              $ 1.01      $  .66      $ 1.57      $ 1.20
                                        ======      ======      ======      ======


</TABLE>





(a) Computed under the "Treasury Stock Method" using the average market price
    for the respective period.

                                  Page 15 of 17
§ 520.1871 Praziquantel and pyrantel. ( a ) *Specifications.* ( 1 ) Each tablet contains 13.6 milligrams (mg) praziquantel and 54.3 mg pyrantel base (as pyrantel pamoate), 18.2 mg praziquantel and 72.6 mg pyrantel base (as pyrantel pamoate), or 27.2 mg praziquantel and 108.6 mg pyrantel base (as pyrantel pamoate).
( 2 ) Each chewable tablet contains 30 mg praziquantel and 30 mg pyrantel pamoate or 114 mg praziquantel and 114 mg pyrantel pamoate.
( b ) *Sponsors.* See sponsors in § 510.600(c) for use as in paragraph (d) of this chapter. ( 1 ) See No. 058198 for use of tablets described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.
( 2 ) See No. 051311 for use of tablets described in paragraph (a)(2) of this section for use as in paragraph (d)(2) of this section.
( c ) *Special considerations.* See § 500.25 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Cats* — ( i ) *Dosage.* Administer a minimum dose of 2.27 mg praziquantel and 9.2 mg pyrantel pamoate per pound of body weight according to the dosing tables on labeling. May be given directly by mouth or in a small amount of food. Do not withhold food prior to or after treatment. If reinfection occurs, treatment may be repeated.
( ii ) *Indications for use.* For removal of tapeworms (*Dipylidium caninum* and *Taenia taeniaeformis*), hookworms (*Ancylostoma tubaeforme*), and large roundworms (*Toxocara cati*) in cats and kittens.
( iii ) *Limitations.* Not for use in kittens less than 2 months of age or weighing less than 2.0 pounds. Consult your veterinarian before giving to sick or pregnant animals.
( 2 ) *Dogs* — ( i ) *Amount.* Administer a minimum dose of 5 mg praziquantel and 5 mg pyrantel pamoate per kilogram body weight (2.27 mg praziquantel and 2.27 mg pyrantel pamoate per pound body weight) according to the dosing tables on labeling.
( ii ) *Indications for use.* For the treatment and control of roundworms (*Toxocara canis* and *Toxascaris leonina*), hookworms (*Ancylostoma caninum*, *Ancylostoma braziliense*, and *Uncinaria stenocephala*), and tapeworms (*Dipylidium caninum* and *Taenia pisiformis*) in dogs and puppies.
[58 FR 58652, Nov. 3, 1993, as amended at 72 FR 16270, Apr. 4, 2007; 75 FR 54018, Sept. 3, 2010; 86 FR 14819, Mar. 19, 2021]
§ 582.5878 Thiamine mononitrate. ( a ) *Product.* Thiamine mononitrate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals Fifth Circuit 

## FILED December 10, 2003 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 03-50929 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus ERNESTO ALONSO QUINTERO-CRUZ, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. EP-03-CR-517-ALL-PRM

-------------------- Before DAVIS, EMILIO M. GARZA, and DENNIS, Circuit Judges.
PER CURIAM: * Ernesto Alonso Quintero-Cruz appeals the sentence imposed following his guilty plea conviction of being found in the United States after deportation/removal in violation of 8 U.S.C. § 1326. Quintero-Cruz contends that 8 U.S.C. § 1326(a) and 8 U.S.C. § 1326(b) define separate offenses. He argues that the prior conviction that resulted in his increased sentence is an element of a separate offense under 8 U.S.C. § 1326(b) that should have been alleged in his indictment. Quintero-Cruz maintains that heNo. 03-50929 -2- pleaded guilty to an indictment which charged only simple reentry under 8 U.S.C. § 1326(a). He argues that his sentence exceeds the two-year maximum term of imprisonment which may be imposed for that offense.
In Almendarez-Torres v. United States , 523 U.S. 224, 235 (1998), the Supreme Court held that the enhanced penalties in 8 U.S.C. § 1326(b) are sentencing provisions, not elements of separate offenses. The Court further held that the sentencing provisions do not violate the Due Process Clause. Id. at 239-47. Quintero-Cruz acknowledges that his argument is foreclosed by Almendarez-Torres , but asserts that the decision has been cast into doubt by Apprendi v. New Jersey , 530 U.S. 466, 490 (2000). He seeks to preserve his argument for further review. Apprendi did not overrule Almendarez-Torres
. See Apprendi , 530 U.S. at 489-90; United States v. Dabeit , 231 F.3d 979, 984 (5th Cir. 2000). This court must follow Almendarez-Torres “unless and until the Supreme Court itself determines to overrule it.” Dabeit , 231 F.3d at 984 (internal quotation marks and citation omitted). The judgment of the district court is
AFFIRMED. The Government has moved for a summary affirmance in lieu of filing an appellee’s brief. In its motion, the Government asks that an appellee’s brief not be required. The motion is GRANTED.
AFFIRMED; MOTION GRANTED.
Editorial Note on Part 108
Editorial Note: Nomenclature changes to part 108 appear at 81 FR 49896, July 29, 2016.

§ 108.6 Revocation of determination of need for permit. ( a ) A permit shall be required only during such temporary period as is necessary to protect the public health.
( b ) Whenever the Commissioner has reason to believe that a permit holder is in compliance with the mandatory requirements and conditions established in subpart B of this part and is likely to remain in compliance, he shall, on his own initiative or on the application of the permit holder, revoke both the determination of need for a permit and the permit that had been issued. If denied, the applicant shall, upon request, be afforded a hearing conducted in accordance with § 108.5 (b) and (c) as soon as practicable. Such revocation is without prejudice to the initiation of further permit proceedings with respect to the same manufacturer, processor, or packer should later information again show the need for a permit.
§ 522.1223 Ketamine, promazine, and aminopentamide. ( a ) *Specifications.* Each milliliter of solution contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity, 7.5 (mg) of promazine hydrochloride, and 0.0625 mg of aminopentamide hydrogen sulfate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Administer by intramuscular injection 15 to 20 mg ketamine base per pound of body weight, depending on the effect desired.
( 2 ) *Indications for use.* It is used in cats as the sole anesthetic agent for ovariohysterectomy and general surgery.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16191, Mar. 25, 2014]
§ 630.20 Exceptions for certain ineligible donors. After assessing donor eligibility under §§ 630.10 and 630.15, an establishment may collect blood and blood components from a donor who is determined to be not eligible to donate under any provision of § 630.10(e) and (f) or § 630.15(a) if one of the following sets of conditions are met: ( a ) The donation is for autologous use only as prescribed by the donor's physician, the donor has a hemoglobin level no less than 11.0 grams of hemoglobin per deciliter of blood or a hematocrit value no less than 33 percent, and the responsible physician determines and documents that the donor's health permits the collection procedure; or
( b ) The donation is collected under a Source Plasma collection program which has received prior written approval from the Director, Center for Biologics Evaluation and Research, to collect plasma for further manufacturing use into in vitro products for which there are no alternative sources, the donor meets the criteria in § 630.10(f)(1) through (6), and the responsible physician determines and documents for each donation that the donor's health permits the collection procedure, and the collection takes place under the medical oversight specified in the approved plasmapheresis program.
( c ) The donation is restricted for use solely by a specific transfusion recipient based on documented exceptional medical need, and the responsible physician determines and documents that the donor's health permits the collection procedure, and that the donation presents no undue medical risk to the transfusion recipient.
# L_2021336DE.01005101.xml

| 23.9.2021 | DE | Amtsblatt der Europäischen Union | L 336/51 |
| --- | --- | --- | --- |

23.9.2021

DE

Amtsblatt der Europäischen Union

L 336/51

---

Berichtigung der Verordnung (EU) 2018/1862 des Europäischen Parlaments und des Rates vom 28. November 2018 über die Einrichtung, den Betrieb und die Nutzung des Schengener Informationssystems (SIS) im Bereich der polizeilichen Zusammenarbeit und der justiziellen Zusammenarbeit in Strafsachen, zur Änderung und Aufhebung des Beschlusses 2007/533/JI des Rates und zur Aufhebung der Verordnung (EG) Nr. 1986/2006 des Europäischen Parlaments und des Rates und des Beschlusses 2010/261/EU der Kommission

(
  Amtsblatt der Europäischen Union L 312 vom 7. Dezember 2018
  )

Seite 86 Artikel 46 Absatz 1 Unterabsatz 2

Anstatt:

„Der Zugang zu den Daten für die in Unterabsatz 1 genannten Stellen wird auf die spezifische Zuständigkeit der betroffenen Stellen begrenzt.“

muss es heißen:

„Der Zugriff auf die Daten durch die in Unterabsatz 1 genannten Stellen erfolgt nach Maßgabe des nationalen Rechts des betreffenden Mitgliedstaats und wird auf die spezifische Zuständigkeit der betroffenen Dienststellen begrenzt.“

---
§ 182.1217 Calcium phosphate. ( a ) *Product.* Calcium phosphate (mono-, di-, and tribasic).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
OFFICE OF THE A-ITORNEY GENERAL OF TEXAS 

AUSTIN 

liononblo H. L. Wa8hbura 

County Auditor 

EarA cautlty 

85ll8toll, Taxa 

mar sir: 

the 46th Leglalaoounty In thh state hariug a population of not: 

leas than two hundred oinetythoumnd (390,000) 

not more than three humIre fifty-fire thousand 

(35S,OOO) aooordlng to the last preoodlag Federal 

Oem!ws, and all tuture Federal Camma.* 

seotion 3 0r the Aot deoiama an emtrgenay and 

provided that the not should t(llpII erteot rr0lr and stt*r Its 

passage. 
442 

Honorable H. L. Washbtlsn, Faga 2 

We are informed by your letter and by tha Comptroller*6 office that Harrlr County had a population or 

three hundred fifty-nine thousand three hundred twmtp 

eight (359,328) inhabitant.8 according to the 1930 Federal 

census. 

n‘e conetrue the above mentioned statute to apply 

to all those oountlee having a population of not less than 

two hundred ninety thousand (290,000) or more than three 

hundred fifty-five thoueand (3SS,OOO) aoaordlng to the la8t 

preoodlng Federal Census and all future Federal Canmu, and 

Harrla county does not oomo within the de8lgnated population bracket. Therefore, you are reapeOtrully advleed that 

it Is the opinion of thLs departmnt that Senate Bill Bo. 

401, Acts ot the 40th Legislature, does not apply to Harrfs 

Colulty. 

Trusting that the foregoing fully answers your 

l.nqulw, we remain 

Yours very truly 

ATTOlWEY GW%W OF TEXAS 

Ardell William6 

Aasl8tant 

ATTORNEY GENERAL OF TEXAS
§ 582.7339 Guar gum. ( a ) *Product.* Guar gum.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 582.6203 Calcium hexametaphosphate. ( a ) *Product.* Calcium hexametaphosphate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Editorial Note on Part 570
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 570.250 Part 6 of a GRAS notice: Narrative. In Part 6 of your GRAS notice, you must include a narrative that provides the basis for your conclusion of GRAS status, in which: ( a ) ( 1 ) You must explain why the data and information in your notice provide a basis for your view that the notified substance is safe under the conditions of its intended use for both the target animal and for humans consuming human food derived from food-producing animals. In your explanation, you must address the safety of the notified substance, considering all animal food (including drinking water) as part of the animal's total diet, taking into account any chemically or pharmacologically related substances in such diet. In your explanation, you must also address the safety of the notified substance in regard to human exposure, considering all dietary sources and taking into account any chemically or pharmacologically related substances;
( 2 ) In your explanation, you must identify what specific data and information that you discuss in accordance with paragraph (a)(1) of this section are generally available, and what specific data and information that you discuss in accordance with paragraph (a)(1) of this section are not generally available, by providing citations to the list of data and information that you include in Part 7 of your GRAS notice in accordance with § 570.255;
( b ) You must explain how the generally available data and information that you rely on to establish safety in accordance with paragraph (a) of this section provide a basis for your conclusion that the notified substance is generally recognized, among qualified experts, to be safe under the conditions of its intended use for both the target animal and for humans consuming human food derived from food-producing animals;
( c ) You must either: ( 1 ) Identify, discuss, and place in context, data and information that are, or may appear to be, inconsistent with your conclusion of GRAS status, regardless of whether those data and information are generally available; or
( 2 ) State that you have reviewed the available data and information and are not aware of any data and information that are, or may appear to be, inconsistent with your conclusion of GRAS status;
( d ) If you view any of the data and information in your notice as exempt from disclosure under the Freedom of Information Act, you must identify the specific data and information; and
( e ) For non-public, safety-related data and information considered in reaching a conclusion of GRAS status, you must explain how there could be a basis for a conclusion of GRAS status if qualified experts do not have access to such data and information.